[go: up one dir, main page]

WO2019123294A2 - Nouvelles utilisations de dérivés pyrazolo pipéridine - Google Patents

Nouvelles utilisations de dérivés pyrazolo pipéridine Download PDF

Info

Publication number
WO2019123294A2
WO2019123294A2 PCT/IB2018/060309 IB2018060309W WO2019123294A2 WO 2019123294 A2 WO2019123294 A2 WO 2019123294A2 IB 2018060309 W IB2018060309 W IB 2018060309W WO 2019123294 A2 WO2019123294 A2 WO 2019123294A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/060309
Other languages
English (en)
Other versions
WO2019123294A3 (fr
Inventor
Jonathan DEANE
Tobias Junt
Pius Loetscher
Barbara Nuesslein-Hildesheim
Ben Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to JP2020533229A priority Critical patent/JP2021507889A/ja
Priority to CN201880078211.3A priority patent/CN111432818A/zh
Publication of WO2019123294A2 publication Critical patent/WO2019123294A2/fr
Publication of WO2019123294A3 publication Critical patent/WO2019123294A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the invention relates to the use of certain pyrazole derivatives in the treatment of diseases and conditions potentially associated with the interaction of Toll like receptors. More specifically, the said treatment pertains to the treatment of neuropsychiatric lupus erythematosus (NPSLE), including central nervous system (CNS)-lupus.
  • NPSLE neuropsychiatric lupus erythematosus
  • CNS central nervous system
  • US 9,126,999 B2 and WO 2018/047081 describes the synthesis and some utilities of certain pyrazolo-piperidine derivatives. Said compounds are known to antagonize the Toll like receptors 7 and 8 (TLR7, TLR8) and shall be useful in the treatment of SLE and lupus nephritis. However, US 9,126,999 B2 and WO 2018/047081 are silent with respect to treatment of NPSLE.
  • NPSLE The underlying pathophysiologic mechanisms of NPSLE, including CNS-lupus, are still largely unknown.
  • the present invention provides a novel method for treating and/or preventing NPSLE in a subject in need of such treatment, comprising administering an effective amount of a TLR7/TLR8 antagonist such as a compound of formula (I) or a compound of Formula (II); or a pharmaceutically acceptable salt thereof to a patient suffering from NPSLE .
  • a TLR7/TLR8 antagonist such as a compound of formula (I) or a compound of Formula (II); or a pharmaceutically acceptable salt thereof to a patient suffering from NPSLE .
  • Figure 1 Efficacy of compound of Formula (lb) on systemic disease parameters in the NZBW/F1 model.
  • Figure 2 Efficacy of compound of Formula (lie) on systemic and neuropathological disease parameters in NZBW/F1 model.
  • the invention provides a compound of formula (I) or a
  • Ri is hydrogen, or Ci-C 4 alkyl optionally substituted one or more times by halogen;
  • R 2 and R 3 are independently from each other hydrogen or Ci-C 6 alkoxy
  • R 4 is hydrogen or Ci-C 6 alkyl
  • R 5 is hydrogen or Ci-C 6 alkyl.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in accordance to the first embodiment, wherein
  • Ri is Ci-C 4 alkyl optionally substituted one or more times by halogen
  • R 2 and R 3 are independently from each other Ci-C 6 alkoxy
  • R 4 is hydrogen or Ci-C 6 alkyl
  • R 5 is hydrogen or methyl.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in accordance to the first embodiment wherein Ri is Ci-C 4 alkyl substituted one or more times by halogen;
  • R 2 and R 3 are independently from each other Ci-C 6 alkoxy
  • R 4 is hydrogen or Ci-C 6 alkyl
  • R 5 is hydrogen
  • the invention provides a compound of formula (I) or a
  • R 2 and R 3 are both methoxy
  • R 4 is hydrogen
  • R 5 is hydrogen or methyl.
  • the invention provides a compound of formula (I) or a
  • the invention provides a compound of formula (I) or a
  • the invention provides a compound of formula (I) or a
  • the invention provides a compound of Formula (II) or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of NPSLE.
  • Compounds of Formula (II) or pharmaceutically acceptable salts thereof are represented by the following structure:
  • L is -CH2- or -CH2CH2-
  • R 2 is H, Ci-C 6 alkyl or CrC 6 haloalkyl
  • R 3 is H, Ci-C 6 alkyl or -CD 3 ;
  • R 4 is H, NH 2 , CrC 6 alkyl or halo;
  • each R 5 is independently selected from Ci-C 6 alkyl, -CD 3 and -(CH 2 )nOR 7 ;
  • R 6 is a C 3 -C 6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members
  • N independently selected from N, NH, N(Ci-C 6 alkyl) and O which is unsubstituted or is substituted with 1 -2 R 9 groups;
  • each R 7 is independently selected from H and Ci-C 6 alkyl
  • each R 8 is independently selected from Ci-C 6 haloalkyl, -(C(R 7 ) 2 ) n OR 7 and a CrC 6 alkyl
  • each R 9 is independently selected from Ci-C 6 alkyl, hydroxyl, halo and a Ci-C 6 alkyl substituted with 1 to 3 -OH;
  • n 1 , 2, 3, 4, 5 or 6;
  • n 1 , 2, 3, 4, 5 or 6.
  • the invention provides a compound of Formula (II), or a pharmaceutically acceptable salt thereof, for use according to embodiment 8, wherein said compound is a compound of Formula (lla):
  • R 2 is H, Ci-C 6 alkyl or Ci-C 6 haloalkyl
  • R 3 is H, Ci-C 6 alkyl or -CD 3 ;
  • R 4 is H, NH 2 , Ci-C 6 alkyl or halo
  • R 6 is a C 3 -C 6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, N(CrC 6 alkyl) and O which is unsubstituted or is substituted with 1 -2 R 9 groups;
  • each R 9 is independently selected from Ci-C 6 alkyl, hydroxyl, halo and a Ci-C 6 alkyl substituted with 1 to 3 -OH;
  • the invention provides a compound of Formula (I la), or a pharmaceutically acceptable salt thereof, for use according to embodiment 9, wherein
  • R 2 is Ci-C 4 alkyl
  • R 3 is Ci-C 4 alkyl
  • R 4 is Ci-C 4 alkyl or halo
  • R 6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, N(C C 6 alkyl) and O.
  • the invention provides a compound of Formula (I la), or a
  • R 2 is Ci-C 4 alkyl
  • R 3 is Ci-C 4 alkyl
  • R 4 is Ci-C 4 alkyl.
  • the invention provides a compound of Formula (II), (lla) or (lib), or a pharmaceutically acceptable salt thereof, for use according to any one of embodiment 8 to 1 1 , wherein the compound is (S)-/V-(4-((5-(1 ,6-dimethyl-1 /-/-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl- 4,5,6,7-tetrahydro-1 /-/-pyrazolo[4,3-c]pyridin-1 -yl)methyl)bicyclo[2.2.2]octan-1 -yl)morpholine-3- carboxamide; or a pharmaceutically acceptable salt thereof.
  • This compound is also represented by
  • the invention provides a compound of Formula (lie) in its free form for use according to any one of embodiment 8 to 1 1 .
  • the invention provides a compound of Formula (lie) in a hydrate form for use according to any one of embodiment 8 to 1 1 .
  • the invention provides a crystalline form of a hydrate of (S)-/V-(4-((5- (1 ,6-dimethyl-1 /-/-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1 /-/-pyrazolo[4,3-c]pyridin- 1 -yl)methyl)bicyclo[2.2.2]octan-1 -yl)morpholine-3-carboxamide in for use according to any one of embodiment 8 to 1 1 .
  • the invention provides a crystalline form of a heptahydrate of (S)-/V-(4-((5-(1 ,6-dimethyl-1 /-/-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl- 4,5,6,7-tetrahydro-1 /-/-pyrazolo[4,3-c]pyridin-1 -yl)methyl)bicyclo[2.2.2]octan-1 -yl)morpholine-3- carboxamide in for use according to any one of embodiment 8 to 1 1 .
  • Such crystalline form is described in patent application PCT/CN2018/087448 filed on May 18, 2018 (attorney docket number: PAT058103-WO-PCT) which is hereby incorporated by reference.
  • neuropsychiatric systemic lupus erythematosus refers to different neurological and/or behavioral clinical syndromes in patients suffering from systemic lupus erythematosus (SLE), which includes central nervous system (CNS) manifestations (CNS-lupus) and neuropathies in the peripheral nervous system (PNS).
  • SLE systemic lupus erythematosus
  • CNS central nervous system
  • NPS-lupus central nervous system
  • PNS peripheral nervous system
  • the neuropsychiatric manifestations of lupus vary from mild to severe (see Kivity et al. BMC Med. 2015 Mar 4; 13:43) and affect up to 75% of patients with SLE.
  • the effect of neuropsychiatric manifestations on disease severity, quality of life, and prognosis is considered one of the major causes of morbidity and mortality in patients with SLE.
  • the present invention relates to the treatment of NPSLE patients typically via inhibition of the Toll-like receptors (TLR), and may especially include the inhibition of TLR7.
  • TLR Toll-like receptors
  • the present invention relates to a compound of formula (I) or a compound of Formula (II) in accordance to any one of embodiments 1 to 12, or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a compound of Formula (II) or a compound according to any one of the embodiments 1 to 12; or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carrier for use in the treatment and/or prevention of NPSLE.
  • the present invention provides a method for treating and/or preventing NPSLE in a patient in need thereof comprising administering an effective amount of a compound of Formula (I) wherein the compound is as described in any one of embodiments 1 to 7; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for treating and/or preventing NPSLE in a patient in need thereof comprising administering an effective amount of a compound of Formula (II), wherein the compound is as described in any one of embodiments 8 to 12; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for treating and/or preventing NPSLE in a patient in need thereof comprising administering a pharmaceutical composition comprising an effective amount of a compound of formula (I) in accordance to any one of embodiments 1 to 7; or a pharmaceutically acceptable salt thereof and one or more
  • the present invention provides a method for treating and/or preventing NPSLE in a patient in need thereof comprising administering a pharmaceutical composition comprising an effective amount of a compound of formula (II) in accordance to any one of embodiments 8 to 12; or a pharmaceutically acceptable salt thereof and one or more
  • the present invention provides the use of a compound in accordance to formula (I) in accordance to any one of embodiments 1 to 7, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and/or preventing NPSLE.
  • the present invention provides the use of a compound in accordance to formula (II) in accordance to embodiment 7 to 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and/or preventing NPSLE.
  • a compound in accordance to formula (II) in accordance to embodiment 7 to 12 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating and/or preventing NPSLE.
  • alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, /so-propyl, n-butyl, sec-butyl, /so-butyl, tert- butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
  • alkoxy refers to alkyl-O-, wherein alkyl is defined herein above.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2- propoxy, butoxy, tert- butoxy, pentyloxy, hexyloxy, and the like.
  • alkoxy groups typically have about 1 -6, more preferably about 1-4 carbons.
  • halogen refers to a fluoro, chloro, bromo or iodo radical or residue.
  • Halogen may preferably be fluoro.
  • alkyl optionally substituted one or more times by halogen may for example refer to methyl, ethyl, propyl, tert- butyl, monofluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, tetrafluoroethyl or pentafluoroethyl.
  • Pharmaceutically acceptable acid addition salts may be formed with inorganic acids and organic acids.
  • Pharmaceutically acceptable base addition salts may be formed with inorganic and organic bases.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g. , acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydr
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • free form refers to the compound per se without salt formation.
  • the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response in a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease (e.g. ameliorating the symptoms associated with NPSLE; alleviating the NPSLE condition, slow or delay the progression of NPSLE)
  • the term“subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human. In some embodiment, human subject is also refered to as patient.
  • primates e.g., humans
  • the subject is a primate.
  • the subject is a human.
  • human subject is also refered to as patient.
  • the term“inhibit”, “inhibition” or“inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term“treat”,“treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e. , slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • ameliorating the disease or disorder i.e. , slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof.
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g. , stabilization of a physical parameter), or both.
  • treating NPSLE refers to treating different neurological and/or behavioral clinical syndromes in patients suffering from systemic lupus erythematosus (SLE).
  • Those neurological and/or behavioral clinical syndromes include 19 syndromes, according to the American College of Rheumatology definition (Arthritis Rheum 1999, 42(4):599-608): aseptic meningitis, cerebrovascular diseases, demyelinating syndrome, headache, movement disorder, myelopathy, seizure disorders, acute confusional state, anxiety disorder, cognitive dysfunction, neuropathy, mood disorder and psychosis as well as the peripheral syndromes Guillain Barre syndrome, autonomic neuropathy, mononeuropathy, myasthenia gravis, cranial neuropathy, plexopathy and polyneuropathy.
  • the term“preventing” refers to delaying the onset or development or progression of the disease or disorder (i.e. delaying the onset or development or progression of the neurological and/or behavioral clinical syndromes as defined above)
  • a subject is“in need of’ a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the ( R )-, (S)- or (Re configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the ( R )- or (S)- configuration.
  • Substituents at atoms with unsaturated bonds may, if possible, be present in cis- ( Z )- or trans- (£)- form.
  • a compound of the present invention may be in the form of one of the possible isomers such as rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric ( cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • positional isomer are not encompassed by the above.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g. , tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0, 0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
  • Racemic products can also be resolved by chiral chromatography, e.g. , high performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) using a chiral adsorbent.
  • HPLC high performance liquid
  • such compounds are administered in therapeutically effective amounts either alone or as part of a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition, which comprises a compound of the invention, or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • solvates and hydrates are generally considered compositions.
  • pharmaceutically acceptable carriers are sterile.
  • the pharmaceutical composition of the present invention may be in unit dosage of about 1- 1000 mg of active ingredient(s) for a subject of about 50-70 kg.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g. , aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g. , as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10 3 molar and 10 9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg.
  • compositions of the invention can be prepared using processes which include admixing a compound of the invention, or pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the pharmaceutical compositions of the inventions are manufactured by mixing, granulating and/or coating methods using a compound of the invention in free form, or in a pharmaceutically acceptable salt form, in association with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g. , vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient may decompose.
  • agents which are referred to herein as "stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, rectal administration, transdermal administration, parenteral, intravenous administration, intramuscular administration, pulmonary administration, inhalation administration, intranasal administration, ophthalmic administration and topical administration.
  • routes of administration such as oral administration, rectal administration, transdermal administration, parenteral, intravenous administration, intramuscular administration, pulmonary administration, inhalation administration, intranasal administration, ophthalmic administration and topical administration.
  • compositions of the invention may be administered orally as discrete dosage forms, wherein such dosage forms include, but are not limited to, capsules, gelatin capsules, caplets, tablets, chewable tablets, lozenges, dispersible powders, granules, syrups, flavored syrups, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or whips, and oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • compositions of the invention comprising an effective amount of a compound of the invention can be made up in a solid form including without limitation capsules, gelatin capsules, hard or soft capsules, tablets, chewable tablets, lozenges, caplets, pills, granules or dispersible powders, or in a liquid form including without limitation solutions, aqueous or oily suspensions, syrups, elixirs, foams, whips or emulsions.
  • compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • conventional pharmaceutical operations such as sterilization and/or may contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
  • diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
  • lubricants e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or
  • binders e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth,
  • disintegrants e.g., starches, agar, alginic acid or its sodium salt, or effervescent
  • Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. Tablets may be either film coated or enteric coated according to methods known in the art.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • compositions of the invention may be administered parenterally by various routes including, but not limited to, subcutaneous, intravenous including bolus injection, intramuscular, and intraarterial.
  • compositions are aqueous isotonic solutions or suspensions.
  • suppositories are advantageously prepared from fatty emulsions or suspensions.
  • compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and typically contain about 0.1 -75%, or about 1 -50%, of the active ingredient.
  • compositions of the invention may be administered by topical application of a pharmaceutical composition containing a compound of the invention in the form of a lotion, gel, ointment, solution, emulsion, suspension or cream.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g. , for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g. , for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • compositions of the invention of the invention may be administered rectally in the form of suppositories, enemas, ointment, creams rectal foams or rectal gels.
  • suppositories are prepared from fatty emulsions or
  • compositions of the invention of the invention may be formulated as a depot preparation.
  • Such formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • such formulations include polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compound of Formula (I) or (II) according to any one of embodiments 1 to 12 is preferably administered by oral route.
  • Compounds of the invention and pharmaceutical compositions provided herein may be administered singly or in combination with one or more additional therapeutic agents, e.g. low molecular weight antimalarials or biologies selected e.g. from anti-CD40 antibodies.
  • additional therapeutic agents e.g. low molecular weight antimalarials or biologies selected e.g. from anti-CD40 antibodies.
  • the combination of the present invention may be in unit dosage of about 1 -1000 mg of active ingredient(s) for a subject of about 50-70 kg.
  • combinations is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.
  • a physician, clinician or veterinarian of ordinary skill may readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are typically demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention may be applied in vitro in the form of solutions, e.g. , aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g. , as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10 3 molar and 10 9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg.
  • the compound of the present invention may be administered either simultaneously, or before or after, with one or more other therapeutic agent.
  • the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • a therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the invention.
  • the additional therapeutic agents used in combination with a compound of the invention include, but are not limited to anti-inflammatory agents, immunomodulatory agents,
  • immunosuppressive agents include cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compunds, inhibitors of B-cell activating factor (BAFF), inhibitors of B- lymphocyte stimulator (BLyS), and steroid hormones, neurological drugs and anticoagulants.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • BAFF B-cell activating factor
  • B-S B- lymphocyte stimulator
  • steroid hormones neurological drugs and anticoagulants.
  • Nonsteroidal anti-inflammatory drugs used in combination with compounds of the invention, include, but are not limited to, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide.
  • NSAIDs used
  • Anti-rheumatic compound used in combination with compounds of the invention include, but are not limited to, methotrexate.
  • Antimalarial compound used in combination with compounds of the invention include, but are not limited to, chloroquine and hydroxycloroquine.
  • Inhibitors of B-cell activating factor include, but are not limited to, belimumab (Benlysta ®), Blisibimod and BR3-Fc.
  • Immunosuppressive agents used in combination with compounds of the invention include, but are not limited to, mycophenolate mofetil (MMF), mycophenolic acid, cyclophosphamide, azathioprine and Laquinimod (5-chloro-N-ethyl-4-hydroxy-1 -methyl-2-oxo- N-phenyl-1 ,2- dihydroquinoline-3-carboxamide).
  • MMF mycophenolate mofetil
  • azathioprine azathioprine
  • Laquinimod 5-chloro-N-ethyl-4-hydroxy-1 -methyl-2-oxo- N-phenyl-1 ,2- dihydroquinoline-3-carboxamide.
  • DHEA dehydroepiandrosterone
  • neurolgocial drugs including but not limited to antidepressants, antiepileptic drugs, antipsychotic drugs could be envisaged. Since thrombi are suspected as one of the causes of NPSLE, a combination with antiplatelet treatments or anticoagulants could be envisaged.
  • IFNAR interferon receptor
  • anti-IFNAR treatment was protective against CNS pathology (reactive microglia, synapse loss, and microglia engulfment of neuronal material), and behavioral phenotypes (published by Bialas et al., Nature 546, pp 539, 2017).
  • a TLR7 antagonist e.g. a compound of the invention, e.g. a compound of formula (I) or in particular a compound of formula (la) or formula (lb), or a compound of Formula (II) and in particular a compound of Formula (I la) or (lib) or (lie) blocks IFNa production, restores B cell tolerance, halts the progression of peripheral autoimmunity and hence reduces CNS pathology in the 564lgi mice lupus model.
  • a TLR7 antagonist e.g. a compound of the invention, e.g. a compound of formula (I) or in particular a compound of formula (la) or formula (lb), or a compound of Formula (II) and in particular a compound of Formula (I la) or (lib) or (lie) blocks IFNa production, restores B cell tolerance, halts the progression of peripheral autoimmunity and hence reduces CNS pathology in the 564lgi mice lupus model.
  • TLR8 is non-functional in rodents.
  • their underlying compounds, including compound of formula (lb) are dual TLR7/8 antagonists.
  • compounds of Formula (II), (I la), (lib) or (lie) are dual TLR7/8 antagonists.
  • the results of the compounds of the present invention may or may not depend on the efficacy of the compound on the TLR7 and the TLR8 receptor, since as eluded above TLR8 is non-functional in rodents. Consequently, the effect of the compounds of the invention obtained in the below animal experiments may not necessarily be linkeable to TLR8.
  • the compound of formula (lb) is a potent TLR7 antagonist, i.e. has an IC 5 o of 35 nM as determined by suppression of IFNa secretion from human peripheral blood mononuclear cells (PBMCs) following stimulation with single stranded RNA (ssRNA) complexed with a liposomal transfection reagent.
  • PBMCs peripheral blood mononuclear cells
  • ssRNA single stranded RNA
  • the compound has also a TLR8 antagonist component as it suppresses TNFa in a similar assay with an IC 50 of 36 nM.
  • the compound of formula (lie) is a potent TLR7 antagonist, i.e. has an IC 50 of 4 nM as determined by huPBMC TLR7 Antagonist IFNa Assay disclosed in WO2018/04081 , filed Septmber 6, 2017.
  • the compound has also a TLR8 antagonist component as it suppresses TNFa in a similar assay with an IC 50 of 166 nM.
  • mice are bled periodically, and blood cells are assayed for expression of interferon stimulated genes (ISGs) by qPCR.
  • CD69 expression is measured from blood following ex vivo R848 stimulation as a pharmacodynamic marker, and compound exposure is determined in blood.
  • mice are sacrificed and spleen and lymph nodes is taken for flow cytometry analysis and immunohistochemistry.
  • This analysis focuses on the frequency of auto-antibody specific (Id pos) B cells, germinal center B cells (GC) and plasmablasts and expression of IFNa. Spleen tissue is harvested for ISG analysis. Anti-nucleolar antibody titers are determined from serum by ELISA.
  • mice are bled periodically, and blood cells are being assayed for expression of interferon stimulated genes (ISGs) by qPCR.
  • ISGs interferon stimulated genes
  • mice will undergo behavioral testing, such as the elevated plus maze, the novelty Y maze, the three-chamber social interaction assay, and pre-pulse inhibition testing.
  • mice are sacrificed for harvesting serum, cerebrospinal fluid (CSF), spleen, and brain tissue for carrying out the following analyses:
  • Spleens are analyzed for ISG expression by qPCR, and for auto-antibody specific (Id pos) B cells, germinal center B cells (GC) and plasmablasts by immunohistochemistry and flow cytometry.
  • Anti- nucleolar antibody titers are determined from serum by ELISA.
  • Brain is analyzed by qPCR for ISGs and microglia is studied by immunohistochemistry and by flow cytometry.
  • CD69 expression is measured from blood following ex vivo R848 stimulation as a pharmacodynamic marker, compound exposure is determined in blood and metabolite levels are determined in serum, brain and CSF.
  • mice which are treated with a compound of Formula (lb) or a compound of Formula (lie) - as opposed to mice of the vehicle group - show reduced progression of NPSLE symptoms, i.e. reduced aberrant behavior in the different behavioral tests, fewer histological and molecular changes to the CNS which are indicative of interferon signaling and neuropathological symptoms, and lower amounts of potentially neurotoxic metabolites.
  • NPSLE The diagnosis of NPSLE defines a subgroup of SLE patients with CNS involvement.
  • the NZBW/F1 mouse model of lupus shows neuropathological symptoms (Bialas et al., Nature 2017 546 (7659): 539-543; Kier et al. J Comp Pathol 1990, 102(2)”165-177), and compound of Formula confers protection on systemic readouts in this model, e.g. kidney pathology ( Figure 1).
  • Figure 1 Efficacy of compound of Formula (lb) on systemic disease parameters in the NZBW/F1 model.
  • NZBW/F1 mice were treated q.d. with 100 mg/kg compound of Formula (lb) p.o. (filled circles) or vehicle (open circles), starting at 28 weeks of age.
  • Proteinuria Uristix, Bayer, Leverkusen, Germany
  • body weight of NZB/W F1 mice were recorded weekly throughout the experiment, starting at 20 weeks of age.
  • Score 0 no protein detected
  • Compound of Formula (lie) was found to reduce specific markers of brain pathology in this model.
  • Compound of Formula (lie) blocked systemic readouts ( Figure 2a, b), and dose-dependently inhibited the expression of NMDAR autoantibodies ( Figure 2c), which are associated with NPSLE in humans (Omdal et al., Eur J Neurol 2005 12(5):392-398; Robbins et al., Arthritis Rheum 1998 31 (5):623-31 ) and directly disturb neuronal function (Faust et al., PNAS 2010, 107(43): 18569-74).
  • compound of Formula (lie) blocked NF-L levels in the circulation ( Figure 2d) and NF-L is a widely used clinical biomarker of inflammatory damage to the CNS (e.g. Cai et al., Neuropsychiatr Dis. Treat, 2018 14:2241 -2254). Since compound of Formula (lie) inhibited serum levels of anti-NMDAR autoantibodies and NF-L, it was demonstrated that compound of Formula (lie) has a neuroprotective role in NPSLE.
  • mice Female 12-week-old NZB/W F1 mice (NZBNZWFI/OlaHsd) were obtained from NZBNZWFI/OlaHsd.
  • Ventilated Cage, IVC at 21 ⁇ 2°C and 55 ⁇ 10% relative humidity with a time-regulated
  • mice received fresh food every two weeks and daily food consumption per mouse was calculated by dividing food intake by the number of days and number of mice per cage. Food consumption was defined as food given minus food left in the cage. Treatment groups
  • mice were assigned to one of four treatment groups:
  • mice Treatments for all mice started on the same day and were maintained until the end of the experiment, i.e. 41 weeks of age. Blood was sampled for drug exposure (PK), PD and ANA measurements at the indicated time points during the experiment.
  • PK drug exposure
  • NZB/W F1 mice were bled from the tail vein (in-life) or by heart puncture (terminal) into micro tubes Z-gel (Sarstedt, Niimbrecht, Germany). Serum was isolated by centrifugation (10000 g, 10 min, RT) and kept at -80°C.
  • Nunc Maxisorp plates (Huberlab, Aesch, Switzerland) were coated in PBS at 4°C overnight with either diluted 100 mg/ml salmon sperm DNA (Thermo Fisher Scientific, Waltham, MA), 10 mg/ml calf thymus histone (Sigma-Aldrich, St.
  • Serum dilutions of 1 :100 or 1 :300 in PBS/1 % BSA (100 pi) were added for 2 h at RT, plates were washed in PBS/0.05% Tween-20 and HRP-conjugated isotype-specific detection antibodies were added for 2 h at RT (1/5000 for polyclonal goat anti-mouse IgG 1 , polyclonal goat anti-mouse lgG2a, polyclonal goat antimouse lgG3 and polyclonal goat anti-mouse IgM, all from
  • Percent autoantibody levels were calculated by expressing each autoantibody level for each compound-treated animals as percent, with 100% defined as the mean level of the corresponding autoantibody in the vehicle-treated group. Percentages for anti- Smith, antiribosomal P, and anti-NMDAR (lgG2a, lgG2, IgG) were averaged for a composite score.
  • NF-L Neurofilament light chains in serum were measured using a sandwich ELISA.
  • MultiArray 96 plates (Meso Scale Diagnostics, Rockville, MD) were coated with 50 mI/well of 1 .25 pg/ml anti-NF-L mouse monoclonal antibody (47:3 (UD1 ),
  • Embodiment 1 a A method of treating and/or preventing NPSLE, comprising administering to a patient in need thereof, an effective amount of a compound of formula (II):
  • L is -CH2- or -CH2CH2-
  • R 2 is H, Ci-C 6 alkyl or Ci-C 6 haloalkyl
  • R 3 is H, Ci-C 6 alkyl or -CD 3 ;
  • R 4 is H, NH 2 , CrC 6 alkyl or halo
  • each R 5 is independently selected from Ci-C 6 alkyl, -CD 3 and -(CH 2 )nOR 7 ;
  • R 6 is a C 3 -C 6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, N(Ci-C 6 alkyl) and O which is unsubstituted or is substituted with 1 -2 R 9 groups;
  • each R 7 is independently selected from H and Ci-C 6 alkyl
  • each R 8 is independently selected from Ci-C 6 haloalkyl, -(C(R 7 )2) n OR 7 and a Ci-C 6 alkyl
  • each R 9 is independently selected from Ci-C 6 alkyl, hydroxyl, halo and a CrC 6 alkyl substituted with 1 to 3 -OH;
  • n 1 , 2, 3, 4, 5 or 6;
  • n 1 , 2, 3, 4, 5 or 6; or a pharmaceutically acceptable salt thereof
  • Embodiment 2a The method according to embodiment 1 a wherein said compound is a compound of Formula (lla):
  • R 2 is H, Ci-C 6 alkyl or Ci-C 6 haloalkyl
  • R 3 is H, Ci-C 6 alkyl or -CD 3 ;
  • R 4 is H, NH 2 , Ci-C 6 alkyl or halo
  • R 6 is a C 3 -C 6 cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, N(Ci-C 6 alkyl) and O which is unsubstituted or is substituted with 1 -2 R 9 groups;
  • each R 9 is independently selected from Ci-C 6 alkyl, hydroxyl, halo and a CrC 6 alkyl substituted with 1 to 3 -OH; or a pharmaceutically acceptable salt thereof.
  • Embodiment 3a The method according to embodiment 2a wherein the compound is a compound of Formula (lla) and:
  • R 2 is Ci-C 4 alkyl
  • R 3 is CrC 4 alkyl
  • R 4 is Ci-C 4 alkyl or halo
  • R 6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, N(Ci-C 6 alkyl) and O; or a pharmaceutically acceptable salt thereof.
  • Embodiment 4a The method according to any one of embodiments 1 a to 3a wherein said compound is a compound of Formula (lib):
  • R 2 is Ci-C 4 alkyl
  • R 3 is Ci-C 4 alkyl
  • R 4 is CrC 4 alkyl; or a pharmaceutically acceptable salt thereof.
  • Embodiment 5a The method according to any one of embodiments 1 a to 4a wherein said compound is of Formula (lie):
  • Embodiment 6a A method of treating and/or preventing NPSLE, comprising administering to a patient in need thereof, an effective amount of a compound of formula (I):
  • Ri is hydrogen, or Ci-C 4 alkyl optionally substituted one or more times by halogen;
  • R 2 and R 3 are independently from each other hydrogen or Ci-C 6 alkoxy
  • R 4 is hydrogen or Ci-C 6 alkyl
  • R 5 is hydrogen or Ci-C 6 alkyl; or apharmaceutically acceptable salt thereof.
  • Embodiment 7a The method in accordance to embodiment 6a, wherein the compound is a compound of Formula (I) and
  • Ri is trifluoro methyl or difluoromethyl
  • R 2 and R 3 are both methoxy
  • R 4 is hydrogen
  • R 5 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
  • Embodiment 8a The method according to embodiment 6a or 7a wherein said compound is a compound of formula (la),
  • Embodiment 10a The method according to any one of embodiments 1 a to 9a, wherein NPSLE refers to different neurological and/or behavioral clinical syndromes in patients suffering from systemic lupus erythematosus (SLE).
  • SLE systemic lupus erythematosus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne l'utilisation de certains dérivés pyrazolo pipéridine dans le traitement de maladies et d'états associés à l'interaction du récepteur de type toll. Plus particulièrement, ledit traitement est un traitement de lupus neuropsychiatrique (NPSLE).
PCT/IB2018/060309 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine Ceased WO2019123294A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020533229A JP2021507889A (ja) 2017-12-22 2018-12-19 ピラゾロピペリジン誘導体の新規な使用
CN201880078211.3A CN111432818A (zh) 2017-12-22 2018-12-19 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17210059.6 2017-12-22
EP17210059 2017-12-22
US201862769635P 2018-11-20 2018-11-20
US62/769,635 2018-11-20

Publications (2)

Publication Number Publication Date
WO2019123294A2 true WO2019123294A2 (fr) 2019-06-27
WO2019123294A3 WO2019123294A3 (fr) 2019-08-01

Family

ID=65201642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060309 Ceased WO2019123294A2 (fr) 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine

Country Status (3)

Country Link
JP (1) JP2021507889A (fr)
CN (1) CN111432818A (fr)
WO (1) WO2019123294A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220502B2 (en) 2018-02-12 2022-01-11 Hoffmann-La Roche, Inc. Sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023135505A1 (fr) * 2022-01-11 2023-07-20 Novartis Ag Antagoniste de tlr7/8 pour le traitement du syndrome de sjögren ou d'une maladie du tissu conjonctif mixte
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
US12157746B2 (en) 2018-06-05 2024-12-03 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
US12252484B2 (en) 2018-09-06 2025-03-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US12421252B2 (en) 2019-11-20 2025-09-23 Hoffmann-La Roche Inc. Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease
US12486273B2 (en) 2019-11-19 2025-12-02 Hoffmann-La Roche Inc. Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126999B2 (en) 2012-05-31 2015-09-08 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
WO2018004081A1 (fr) 2016-06-29 2018-01-04 숭실대학교 산학협력단 Procédé de positionnement sans fil à base de nœud d'essai et dispositif associé
WO2018047081A1 (fr) 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363708B (es) * 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Compuestos de quinolina selectivamente sustituidos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126999B2 (en) 2012-05-31 2015-09-08 Eisai R&D Management Co., Ltd. Tetrahydropyrazolopyrimidine compounds
WO2018004081A1 (fr) 2016-06-29 2018-01-04 숭실대학교 산학협력단 Procédé de positionnement sans fil à base de nœud d'essai et dispositif associé
WO2018047081A1 (fr) 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
A. DAS ET AL., IMMUNITY, vol. 46, 2017, pages 106 - 119
ARTHRITIS RHEUM, vol. 42, no. 4, 1999, pages 599 - 608
BIALAS ET AL., NATURE, vol. 546, 2017, pages 539
BIALAS ET AL., NATURE, vol. 546, no. 7659, 2017, pages 539 - 543
BIALAS ET AL., NATURE, vol. 546, no. 7659, 22 June 2017 (2017-06-22), pages 539 - 543
CAI ET AL., NEUROPSYCHIATR DIS.TREAT, vol. 14, 2018, pages 2241 - 2254
FAUST ET AL., PNAS, vol. 107, no. 43, 2010, pages 18569 - 74
FORSBACH ET AL., J.IMMUNOL., vol. 180, 2008, pages 3729 - 3738
KIER ET AL., J COMP PATHOL, vol. 102, no. 2, 1990, pages 165 - 177
KIVITY ET AL., BMC MED., vol. 13, 4 March 2015 (2015-03-04), pages 43
OMDAL ET AL., EUR J NEUROL, vol. 12, no. 5, 2005, pages 392 - 398
R. FURIE, ARTHRITIS AND RHEUMATOLOGY, vol. 69, 2017, pages 376 - 386
ROBBINS ET AL., ARTHRITIS RHEUM, vol. 31, no. 5, 1998, pages 623 - 31
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220502B2 (en) 2018-02-12 2022-01-11 Hoffmann-La Roche, Inc. Sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
US12157746B2 (en) 2018-06-05 2024-12-03 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US12252484B2 (en) 2018-09-06 2025-03-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US12486273B2 (en) 2019-11-19 2025-12-02 Hoffmann-La Roche Inc. Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12421252B2 (en) 2019-11-20 2025-09-23 Hoffmann-La Roche Inc. Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023135505A1 (fr) * 2022-01-11 2023-07-20 Novartis Ag Antagoniste de tlr7/8 pour le traitement du syndrome de sjögren ou d'une maladie du tissu conjonctif mixte

Also Published As

Publication number Publication date
WO2019123294A3 (fr) 2019-08-01
JP2021507889A (ja) 2021-02-25
CN111432818A (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
WO2019123294A2 (fr) Nouvelles utilisations de dérivés pyrazolo pipéridine
ES3022885T3 (en) Piperidinyl-indole derivatives for use in the treatment of c3 glomerulopathy
RU2617502C2 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
KR20210018203A (ko) Jak 억제제를 사용하는 화농성 한선염의 치료
JP7098214B2 (ja) 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
US20210379043A1 (en) Combination treatment of liver disorders
MX2010011673A (es) 1-aril-3-aminoalcoxi-pirazoles como ligandos sigma para potenciar el efecto analgesico de los opioides y atenuar la dependencia de ellos.
BR112015012842B1 (pt) Compostos derivados de diazol lactama, composição farmacêutica e uso dos mesmos
UA122063C2 (uk) Фармацевтична комбінація, що містить селективний агоніст рецептора s1p1
CN112384220A (zh) sGC刺激剂治疗线粒体障碍的用途
US20160193185A1 (en) Diazole amides
US20250235426A1 (en) Pharmaceutical Combination and Use Thereof
JP2023504194A (ja) インスリン耐性における使用方法のための治療化合物
CA3030232A1 (fr) Derives de pyrimidinone et leurs utilisations pour neutraliser l'activite biologique des chimiokines
JP7518900B2 (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
CN103635190B (zh) 治疗方案
KR20220161476A (ko) 전신 경화증의 치료 방법
KR20240158958A (ko) 암의 치료 및/또는 관리를 위한 stat 억제제와 면역 체크포인트 억제제의 조합
US10259827B2 (en) BMP potentiators
JP2009506036A (ja) ピロロピリジン、ピロロピリミジンおよびピラゾロピリジン化合物、それらを含む組成物、ならびにそれらの使用方法
AU2022256612B2 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
RU2569732C9 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
HK40109116A (en) Novel uses of piperidinyl-indole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020533229

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2